

**WORLD ANTI-DOPING AGENCY**

**MEETING OF THE HEALTH, MEDICAL & RESEARCH COMMITTEE**

**September 7th, 2003  
MONTREAL, CANADA**

**SUMMARY NOTES**

**Present:**

- A. Ljungqvist (Chair)
- C. Ayotte
- G. Wadler
- E. DeRose
- T. Friedmann
- B. Drinkwater
- K. Muller
- K. Fitch
- J.C. Mbanya
- B. Saltin (by phone for items 1 to 5)

**Apologies:**

- M. Irie

**Staff:**

- A. Garnier
- O. Rabin

**1) Welcome**

The Chair (A. Ljungqvist) welcomed the Committee and thanked all participants for their availability and for taking the time to attend.

This meeting was very important in the scientific activities of WADA.

The Chair emphasized the need for more than one HM&R meeting per year.

Welcome by David Howman (Acting WADA Director General):

Emphasized on the importance of Science within WADA, and in particular for the elaboration on some of the WADA International Standards to be presented for approval to the WADA Executive Committee at the end of September. Wishes of an excellent meeting with constructive and consensual outcomes.

## 2) **Agenda of the day**

Approved.

## 3) **Review and Approval of Previous Meeting Summary Notes**

The minutes of previous meeting (October 29<sup>th</sup>, 2002), were reviewed and accepted with no modifications.

O. Rabin indicates that in the future it would be necessary to have approval of minutes by circulation to avoid long approval delay.

Also the minutes should be presented as a summary of the point(s) discussed with conclusions, unless some different views need to be recorded.

Finally, it is proposed that HM&R members responsible for action(s) should be clearly identified with a bullet point.

## 4) **Research Projects:**

Comments made that missing information on application form, make scientific reviews more difficult.

Need to modify the application form to include request for preliminary data and to summarize all important information on first four pages. (**Action:** O. Rabin with C. Ayotte, T. Friedmann, B. Saltin.)

Review of research projects: Presentation of all the 33 projects submitted to WADA in 2003, with discussions based upon the independent scientific reviews. Out of 33 projects presented, 9 projects have been selected by the HM&R Committee members and are recommended for approval by the WADA Executive Committee.

Budget committed for 2003 appears very reasonable, and HM&R Committee Members unanimously support the need to obtain a budget at least in the order of the previous years, and use the remaining fraction not committed to 2003 research projects, to target some key projects not submitted by applicants. Several issues deemed of high importance by WADA HM&R Committee, are not addressed by applications and could be covered if WADA could have the resources to contact laboratories directly to agree upon protocols and initiate such research projects.

**5) EPO Testing:**

HM&R Committee acknowledges the fact that some rare EPO urinary profiles are more difficult to read and recommends that WADA send a note to the accredited laboratories to provide guidance on the test.

**6) List Standards:**

Presentation of the 2004 prohibited List as proposed by the List Sub-Committee; some additional changes are discussed by HM&R Committee Members.

The 2004 List will be presented to the WADA Executive Committee for further discussion and approval.

**7) TUE Standards:**

No particular changes brought to the version drafted by the TUE Sub-Committee to be presented to the WADA Executive Committee for approval.

**8) hGH and HBOCs:** O. Rabin made an update on progress of hGH and HBOCs detection methods.

Experts meeting scheduled in October for these two methods.

**9) Neutraceuticals:** WADA's HM&R Committee recommends preparation by the Science and Education Department of a WADA official position paper on this issue.